Original-Research: MagForce AG - von GBC AG Einstufung von GBC AG zu MagForce AG Unternehmen: MagForce AG ISIN: DE000A0HGQF5 Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 11.00 Euro Kursziel auf Sicht von: 31/12/2021 Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Successful completion of Phase 2a trial for the treatment of prostate cancer; market approval expected in 2021; forecasts and BUY price target confirmed MagForce AG has announced the successful completion of Stage 2a of the pivotal trial for the treatment of prostate cancer in the United States. As expected, the treatment group of 10 patients experienced only minimal treatment-related side effects, comparable to those of the first study phase. Prior to the start of the second study phase, MagForce AG had established a streamlined one-day treatment procedure, which enables patient treatment within just one day. Especially against the background of the current Covid 19 pandemic, but also outside the current pandemic situation, a single clinic visit is of great advantage. Even in this streamlined procedure, the side effects observed were only minor. In our previous projections, we had expected patient treatment to be completed by the end of 2020 and the final pivotal study 2b to begin in early 2021. We see the company's latest announcement as a confirmation of this, especially as the company is currently preparing for the start of study phase 2b, which should start early in the second quarter of 2021. Following FDA approval, MagForce management expects marketing to begin in the second half of 2021, which is also fully in line with our previous expectations. In the final study phase 2b, which is important for market approval, up to 120 male patients are to be enrolled at the three MagForce centres in Texas, Washington and Florida. The aim of the study is to show that treatment with the MagForce technology, prostate cancer patients can remain in the so-called 'active surveillance programme' for longer. The disease pattern of patients included in this programme requires close monitoring, but surgery or radiation is not necessary. For patients, staying longer in this stage is associated with a gain in quality of life and the avoidance of side effects. For the health care system, the avoidance of surgical interventions means savings effects that are significant in view of the high number of prostate diseases. We therefore expect a high level of acceptance for the MagForce treatment after market approval. In view of the confirmation of the approval timetable relevant for our forecasts so far, we leave our previous sales and earnings forecasts unchanged. While revenue from the treatment of prostate cancer patients in the US should not visibly increase until the coming 2022 financial year, MagForce AG should primarily report revenue from glioblastoma treatment in Europe in the current 2021 financial year. The management statement that a tripling of commercial glioblastoma treatments is expected in 2021 compared to 2020 still applies. We continue to expect the EBITDA break-even to be reached from 2022 onwards, i.e. from the significant increase in sales in the prostate area. Based on the unchanged forecasts, we confirm our price target of EUR11.00 per share. We continue to assign the BUY rating. Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/22102.pdf Kontakt für Rückfragen Jörg Grunwald Vorstand GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 firstname.lastname@example.org ++++++++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,6a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: http://www.gbc-ag.de/de/Offenlegung +++++++++++++++ Date (time) of completion: 11/02/2021 (08:38 am) Date (Time) first distribution: 11/02/2021 (9:30 am) -------------------übermittelt durch die EQS Group AG.------------------- Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.